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Abstract
In the last 30 years the leprosy burden has been dramatically reduced but over the last 5 years still
more than 200,000 new cases were detected each year. Advances in immunology, pathogenesis, and
genetics of leprosy have been reported. A deeper understanding of the mechanisms of infection will
ultimately improve our ability to fight against this potentially devastating infectious disease.
Introduction and context
Leprosy is a human chronic infectious disease caused by
Mycobacterium leprae. It affects the skin and peripheral
nerves and can cause irreversible impairment of nerve
function and consequent chronic disabilities. Only a
small percentage (less than 1%) of the population that
comes into contact with M. leprae will develop the
disease [1]. Since the introduction of multidrug therapy
in 1982 by the World Health Organisation the leprosy
burden has been dramatically reduced, but over the last
5 years more than 200,000 new detected cases were still
being reported each year [1,2].
The hallmark of leprosy is a broad clinical spectrum of
pathology determined by the host immune response.
Tuberculoid (TT) leprosy patients mount a vigorous
T-helper 1 (Th1) cell-mediated immune response in skin
and nerves, displaying a delayed-type hypersensitivity
response to M. leprae antigens. Although limiting the
number of bacilli and lesions, this strong response
accounts for the prominent impairment of the peripheral
nerves [1]. Conversely, lepromatous (LL) leprosy
patients exhibit specific cellular unresponsiveness to
M. leprae antigens associated with a T-helper 2 (Th2)
immune response and high mycobacterial loads in the
skin and nerves. However, most leprosy patients display
a pathogenesis between the two polar forms and are
classified as either borderline tuberculoid or borderline
lepromatous. Leprosy reactions are common in these
immunologically unstable borderline groups and
involve an upregulation of the host response to
M. leprae antigens [1,2]. In patients with the dissemi-
nated form, lepromatous leprosy, a reaction known as
erythema nodosum leprosum (ENL) is frequent, being
observed in up to 50% of lepromatous leprosy patients
receiving antimicrobial therapy [1,2].
Research into the mechanisms underlying infection,
pathogenesis, and clinical sequelae has been limited by
the fact that M. leprae infects only humans and cannot be
cultured in vitro. However, the complete sequence of the
genome of M. leprae was published at the beginning of
the 21st century [3]. Today, accumulated evidence clearly
indicates that exposure to M. leprae is necessary but not
sufficient to explain susceptibility to leprosy, and several
genes and genomic regions have been implicated as
players in the complex genetic mechanism controlling
host susceptibility to the disease [1].
Recent advances
Immune response
An effective innate immune response in combination
with the low virulence of the leprosy bacillus may
underlie resistance to the development of clinical
disease. Dendritic cells (DCs) uptake M. leprae and
subsequent local production of cytokines and chemo-
kines regulates inflammation and influences the course
of the adaptive cell-mediated immunity into a Th1 or
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presenters of M. leprae antigens, major histocompa-
tibility complex (MHC) class I and II expression is
downregulated in monocyte-derived DCs infected with
M. leprae bacilli. On the other hand, DCs stimulated with
M. leprae membrane antigens upregulate both MHC class
II and CD40 ligand-associated interleukin-12 (IL-12)
production, suggesting that whole live bacilli may
suppress the interaction of DCs and T cells [4].
The cytokine profile present in the lesion also appeared to
be correlated with Toll-like receptor (TLR) function: Th1-
type cytokines are associated with TLR1 and TLR2
activation, and Th2-type cytokines are associated with
inhibition of activation. The expression of TLR1 and TLR2
has been found to be stronger on monocytes and DCs in
TT lesions than in the LL counterparts. In addition, in vitro
studies showed that the M. leprae 19-kDa and 33-kDa
lipoproteins could activate monocytes and monocyte-
derived DCs through TLR2 [5].
Recent investigations showed that plasmacytoid DCs are
not involved in the immune response against M. leprae
whereasFoxP3-positivecells(markersofregulatoryTcells,
or Treg cells) were present in 95% of the cases in a
retrospective immunohistochemical study, with an aver-
age density of 2.9% of the infiltrate. Their distribution
was not related to granulomatous structures or special
locations [6].
Helminthic co-infection and leprosy
Since similar investigations in tuberculosis, a significant
association between intestinal helminthic infections and
multibacillary leprosy has also been reported [7,8].
Intestinal helminths are known to elicit a strong systemic
Th2-type response, which is normally followed by a
reduction in Th1-type immunity. It is possible that the
presence of intestinal helminths downregulates the
required Th1-type immunity via upregulation of Th2-
type cytokine production, facilitating a subsequent
infection by M. leprae. Evidence that Th1 downmodula-
tion occurs during intestinal helminth infection was
provided by the fact that intracellular interferon-gamma
(IFN-g) levels in both tuberculoid and lepromatous,
helminth-free leprosy patients were approximately two-
fold higher than in helminth-infected leprosy patients.
Conversely, lepromatous patients harboring intestinal
helminths produced close to twofold more IL-4 and
IL-10 than helminth-free leprosy patients [8].
Diniz and colleagues [9] recently reported a significant
association between intestinal helminth infections and
lepromatous leprosy and observed that the frequency of
intestinal helminths correlated strongly with the
mycobacterial index. Again, intracellular levels of IFN-g
weresignificantlydecreased in leprosypatientsco-infected
with intestinal helminths when compared with leprosy
patients without worms. Conversely, lepromatous leprosy
patients with intestinal worms produced higher levels of
both IL-4 and IL-10. Results suggest and confirm that a
pre-existing infection by intestinal helminths may facil-
itate the establishment of M. leprae infection or its
progression to a more severe form of leprosy [9].
Alternative mechanisms of infection
Recent work has suggested that the successful infection
and survival of M. leprae could be associated with the
ability of M. leprae to regulate cytokine production or to
drive Th1 or Th2 responses. Other pathways like insulin-
like growth factor could be implicated [10]. Lipid droplet
(LD) formation and prostaglandin 2 (PGE2) production
are directly correlated, indicating that M. leprae-induced
LDs constitute intracellular sites for eicosanoid synthesis
and that foamy cells may be critical regulators in
subverting the immune response in leprosy [11].
Neutrophil recruitment
One of the histological differences between ENL and
lepromatous leprosy is the characteristic infiltration of
neutrophils in ENL lesions. Lee and colleagues [12]
investigated the mechanisms of neutrophil recruitment
at the site of disease. The gene expression profile of ENL
lesions comprised an integrated pathway of TLR2 and Fc
receptor activation, neutrophil migration, and inflam-
mation. Major aspects of this pathway include the
following: (a) FcR or TLR2 induction of IL-1b release;
(b) endothelial activation, including the upregulation of
E-selectin and subsequent neutrophil binding; and (c)
upregulation of inflammatory mediators associated with
both neutrophils and monocytes/macrophages. Thali-
domide, which is a highly effective agent used in the
treatment of ENL and is known to reduce neutrophil
infiltration in lesions, targeted individual events in this
inflammatory pathway [12].
Biomarkers
Comparative analysis of serum proteome of leprosy
patients by two-dimensional electrophoresis followed by
mass spectrometry showed differential expression of
acute-phase protein alpha-1-acid glycoprotein (AGP).
AGP levels in untreated ENL cases were significantly
higher when compared with lepromatous leprosy. After
treatment with thalidomide, the levels of AGP decreased
to normal levels [13].
Leprosy genes and genomic loci
Studies indicate that leprosy pathogenesis is a two-step
process in which a group of genes controls susceptibility
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clinical manifestation of disease. Recent evidence sug-
gests the existence of a third set of genes influencing the
development, in a proportion of affected individuals, of
leprosy reversal reaction type 1 (RR1).
Concerning human leukocyte antigen (HLA) genes, a
strong association has been described between leprosy
and HLA-DRB1, HLA-DQA, HLA-linked genes (such as
TAP, MICA, and MICB), and two microsatellite markers
of the tumor necrosis factor-alpha (TNFA) gene located
in the HLA region. Nonetheless, a positive association
between leprosy and alleles of HLA-linked genes must be
interpreted with caution due to the linkage disequili-
brium phenomenon [14-17].
Numerous non-HLA variants located in different genes,
such as the vitamin D receptor (VDR), the natural
resistance-associated macrophage protein 1 (NRAMP1),
the IL-10, and the PARK2/PACRG genes, have been
described as leprosy genetic risk factors. Two single-
nucleotide polymorphisms (SNPs) located at the reg-
ulatory region shared by the PARK2 and PACRG genes at
chromosomal region 6q25-q27 were found to be
independently associated with leprosy susceptibility per
se in both a Vietnamese and a Brazilian population [18-
20]. The chromosomal region 10p13 has been linked to
paucibacillary leprosy in two independent studies. The
MRC1 gene, encoding the human mannose receptor, is
located in the 10p13 region, and nonsynonymous SNPs
in exon 7 of the gene have been suggested as leprosy
susceptibility factors. Alter and colleagues [21] deter-
mined that G396S is the only nonsynonymous exon 7-
encoded polymorphism after studying 396 unrelated
Vietnamese subjects.
A recent genome-wide study observed a significant
association between SNPs in the genes CCDC122,
C13orf31, NOD2, TNFSF15, HLA-DR, and RIPK2 and a
trend toward an association with an SNP in LRRK2. The
associations between the SNPs in C13orf31, LRRK2,
NOD2,a n dRIPK2 and multibacillary leprosy were
stronger than the associations between these SNPs and
paucibacillary leprosy [22]. Another interesting aspect of
the study is that variation in some of the implicated
genes is known to be associated with bowel inflamma-
tory conditions. A frame-shift mutation in NOD2 has
been identified as a strong susceptibility factor for
Crohn’s disease. Likewise, variants of TNFSF15 and
IL-12B have been associated with Crohn’sd i s e a s e .
These findings are consistent with studies of mouse
models that have also established a role for Nod2, Ripk2,
and Nfkb in intestinal homeostasis and colitis. Together,
these studies establish a strong genetic and functional
link between susceptibility to leprosy and predisposition
to Crohn’s disease [22,23]. Alleles of an SNP and a
microsatellite marker of the TLR2 gene were the first
genetic variants associated with protection and suscept-
ibility to RR1, respectively. Two subsequent reports
demonstrated an impact of TLR1 gene variants over the
risk of occurrence of RR1 [24,25].
Variability and phylogeography of Mycobacterium leprae
New opportunities for understanding the transmission
of M. leprae and its phylogeny have arisen following the
determination of the complete genome sequence by
the group led by Stewart Cole [26]. A notable feature of
the M. leprae genome is the exceptionally large number
of pseudogenes, which occupy almost half of the
genome. Initial analysis of SNPs demonstrated that
genetic variability between different isolates of M. leprae
was very rare. Furthermore, all extant isolates of M. leprae
were nearly indistinguishable, belonging to one of only
four SNP types, and are derived from a single clone [26].
Monot and colleagues [26] recently described the
complete genome sequence and comparative analysis
of a Brazilian strain of M. leprae, Br4923, which was
compared with the genomes of strains from North
America, Thailand, and India. Monot and colleagues
discovered that the four strains share 99.995% sequence
identity. These results are consistent with the hypothesis
that leprosy has arisen from infection with a single clone
that has passed through a recent evolutionary bottleneck.
Differences were found in only 215 polymorphic sites,
mainly SNPs, and in 5 pseudogenes. Sixteen interrelated
SNP subtypes were defined by genotyping both extant
and extinct strains of M. leprae from around the world.
The 16 SNP subtypes showed a strong geographical
association that reflects the migration patterns of early
humans and trade routes, with the Silk Road linking
Europe to China having contributed to the spread of
leprosy [26].
Implications for clinical practice
Leprosy forms a spectrum of clinical manifestations that
correlate with the immune response to the pathogen,
M. leprae. This spectrum is dynamic, with patients
developing immune reactions. Leprosy can be seen as a
model of a number of phenotypes, ranging from other
infectious diseases to several aspects of the immune
response.
In terms of the diagnosis, treatment, and prevention of
leprosy, the finding that four strains of M. leprae from
widely separated countries have genomes that are
99.995% identical is extremely encouraging. These data
mean that antigenic drift in M. leprae should be
negligible and that the sequences of drug targets will
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investigators to understand the phylogeography of
M. leprae.
In the future, biomarkers for reactional stages could aid
in early diagnosis, efficient treatment, prevention of
neurological complications, and prediction of predis-
position to reactional stages. Validation of AGP as an
ENL-specific biomarker and treatment indicator has to
be confirmed.
The significant association between the presence of
intestinal helminths and multibacillary leprosy suggests
and supports the implementation of antihelminthic
strategies in endemic areas, and this may improve
general health and reduce the burden of mycobacterial
infections. Further studies on this issue have to be
conducted.
The description of the pathogenesis and the genetic basis
of susceptibility to leprosy may lead to better protocols
for diagnosis, treatment, and prevention of disease.
Clinicians will not yet reap benefits from the genetic
studies or from the advances in immunopathogenesis of
leprosy as described above. At the moment, no changes
to clinical practice can be recommended. The hope is that
a deeper understanding of the mechanisms of infection
will ultimately improve our ability to fight against a
potentially devastating infectious disease.
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